



(51) International Patent Classification:  
C07C 43/00 (2006.01)

(21) International Application Number:  
PCT/US2011/060747

(22) International Filing Date:  
15 November 2011 (15.11.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
61/413,519 15 November 2010 (15.11.2010) US

(71) Applicant (for all designated States except US): **AD-VENTRX PHARMACEUTICALS, INC.** [US/US];  
12390 El Camino Real, Suite 150, San Diego, California  
92130 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **EMANUELE, Martin**  
[US/US]; 15234 Maple Grove Lane, San Diego, California  
92131 (US).

(74) Agents: **PRATT, John S.** et al.; Kilpatrick Townsend &  
Stockton LLP, Suite 2800, 1100 Peachtree Street, Atlanta,  
Georgia 30309 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: METHODS FOR ENHANCING OXYGENATION OF JEOPARDIZED TISSUE

(57) Abstract: Methods of use of specific polyoxyethylene/polyoxypropylene copolymers as therapeutic agents to enhance the oxygenation of jeopardized tissue by improving delivery of oxygen by damaged erythrocytes and/or to jeopardized tissues, preventing the development of disorders such as anemia, trauma, hypovolemia, inflammation, sepsis, microvascular compromise, sickle cell disease, acute chest syndrome, peripheral artery disease, myocardial infarction, stroke, peripheral vascular disease, macular degeneration, acute respiratory distress syndrome (ARDS), multiple organ failure, ischemia (including critical limb ischemia), hemorrhagic shock, septic shock, acidosis, hypothermia, and anemic decomposition, decreasing the need for transfusions, improving organ transplantation and improving the safety and efficacy of blood transfusions.



WO 2012/068079 A1